Withdrawal-related adverse events from clinical trials of clobazam in Lennox–Gastaut syndrome

@article{Tolbert2014WithdrawalrelatedAE,
  title={Withdrawal-related adverse events from clinical trials of clobazam in Lennox–Gastaut syndrome},
  author={Dwain T Tolbert and Stuart I. Harris and Ihor Bekersky and Deborah M Lee and Jouko Isojarvi},
  journal={Epilepsy & Behavior},
  year={2014},
  volume={37},
  pages={11-15}
}
To assess withdrawal-related adverse event (AE) rates following abrupt clobazam discontinuation in Phase I trials and gradual clobazam tapering (2-3 weeks) following discontinuation from III trials met the criteria for potential/III trials, we evaluated AE data from four multiple-dosage Phase I trials (duration: 8-34 days). Therapeutic (20 and 40 mg/day) and supratherapeutic clobazam dosages (120 and 160 mg/day) were administered. Adverse events (AEs) were also assessed for patients with Lennox… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Similar Papers

Loading similar papers…